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Abstract: Hydrogel nanoparticles—also referred to as polymeric nanogels or 
macromolecular micelles—are emerging as promising drug carriers for therapeutic 
applications. These nanostructures hold versatility and properties suitable for the delivery 
of bioactive molecules, namely of biopharmaceuticals. This article reviews the latest 
developments in the use of self-assembled polymeric nanogels for drug delivery 
applications, including small molecular weight drugs, proteins, peptides, oligosaccharides, 
vaccines and nucleic acids. The materials and techniques used in the development of 
self-assembling nanogels are also described. 
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1. Introduction 
Nanotechnology is the source of exciting progresses in the drug delivery field, offering suitable 
means for site-specific and time-controlled delivery of small molecular weight drugs, proteins, 
peptides, oligosaccharides, vaccines and nucleic acids [1−5]. Overall, drug delivery is the method of 
administering a bioactive compound to achieve a therapeutic effect, in humans or animals. Drug 
delivery systems are formulations that modify the drug release profile and the ability to cross 
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biological barriers, the biodistribution and pharmacokinetics, improving its efficacy and safety, as well 
as the patient compliance. Nanoformulations for drug delivery include numerous architectural designs 
in terms of size, shape, and materials. Several types of nanoparticles have been tested as potential drug 
delivery systems, including hydrogel nanoparticles (also known as polymeric nanogels or 
macromolecular micelles), dendrimers [6], nanospheres [7], nanocapsules and liposomes [8]. Each 
kind of formulation has characteristic drug loading capacity, particle and drug stability, drug release 
rates, and targeting ability. This review highlights the use of self-assembled hydrogel nanoparticles for 
drug delivery applications. Hydrogels are polymeric networks with three-dimensional configuration 
that absorb large quantities of water or biological fluids. Their water affinity is attributed to the 
presence of hydrophilic groups—such as ether, amine, hydroxyl, sulfate and carboxyl—in the polymer 
chains. Hydrogels can be formulated as macroscopic networks, or confined to smaller dimensions. 
When their size is in the submicron range, they are known as nanogels [9]. Nanogels, or hydrogel 
nanoparticles, have gained considerable attention as one of the most promising nanoparticulate drug 
delivery systems, owing to their unique properties that combine the characteristics of hydrogel systems 
(e.g., rather high water content) with a very small size (nanosize). Hydrogel nanoparticles are 
outstanding drug delivery systems: 
1. The particle size and surface properties can be manipulated to avoid rapid clearance by 
phagocytic cells, allowing both passive and active drug targeting; 
2. Controlled and sustained drug release at the target site, improving the therapeutic efficacy and 
reducing side effects. Drug loading is relatively high and may be achieved without chemical reactions; 
this is an important factor for preserving the drug activity; 
3. Ability to reach the smallest capillary vessels, due to their tiny volume, and to penetrate the 
tissues either through the paracellular or the transcellular pathways; 
4. Potential for administration through various routes, including oral, pulmonary, nasal, parenteral, 
intra-ocular etc. 
This review paper is focused on the self-assembled hydrogel nanoparticles for biomedical 
applications, particularly drug delivery. Self-assembled hydrogel nanoparticles in this context refer to 
nanogels formed from amphiphilic or polyionic polymers. The main properties of nanoparticles, the 
method and materials for their production, and the main applications will be reviewed. 
2. Materials, Properties, Methods 
2.1. Materials 
A wide range of materials may be used for nanogels preparation. Biodegradability is essential to 
avoid organ accumulation, potentially leading to toxicity and other undesirable side effects [10,11]. 
Hydrogel nanoparticles are made either from natural or synthetic polymers. The former possess a high 
variety of functional groups, which allow chemical and biochemical modification resulting in many 
kinds of biopolymer-based materials. Among these, polysaccharides are the more often used. 
Polysaccharides are naturally occurring carbohydrate-based polymers, formed of repeating units 
(monosaccharides) joined together by glycosidic bonds. They may be obtained from algal (alginate), 
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plant (cellulose, starch) and animal (chitosan) sources, exhibit quite variable structures and properties, 
different reactive groups, a wide range of molecular weights and variable chemical composition. 
Polysaccharides can be divided into non-polyelectrolytes (dextran, dextrin, pullulan) and 
polyelectrolyte. Polyelectrolyte polysaccharides may be further divided into positively (chitosan) and 
negatively (heparin, hyaluronic acid) charged. Polysaccharides are highly stable, safe, non-toxic, 
hydrophilic and biodegradable. They are, in addition, abundant natural resources and may be processed 
at low cost.  
Among the more often used synthetic polymers, block copolymers consist of two or more segments 
of simple polymers (blocks) joined in some arrangement. Block copolymers are further classified by 
the number of blocks each molecule contains: two, three, or more blocks correspond to diblocks, 
triblocks, or multiblocks, respectively. Biodegradable and biocompatible poly(D,L lactic acid) (PLA), 
poly(glycolic acid) (PGA) and their copolymer poly(D,L-lactic-co-glycolic acid) (PLGA) have been 
extensively used in controlled drug delivery and have been approved by the US Food and Drug 
Administration [12]. 
2.2. Properties 
The ability of nanodelivery systems to overcome physiological barriers is determined by properties 
such as particle size, surface charge and hydrophobicity. Physiological barriers are biological 
structures or physiologic mechanisms that hinder nanoparticles from reaching their targets, therefore 
compromising the therapeutic efficacy. Nanoparticulate systems able to overcome these biological 
barriers should be capable of: efficient extravazation through the vasculature, prolonged vascular 
circulation time, improved cellular uptake and endosomal escape. 
The endothelial wall in the vasculature presents reduced permeability and constitutes the primary 
barrier for nanoparticles. The nanosize (Figure 1) may facilitate the penetration of nanoparticles across 
the endothelium. It is well known that extravazation of nanoparticles into the brain, across the 
blood-brain barrier, represents a particular difficult challenge for nanomedicine. Small drugs may 
diffuse through the capillary walls into the tissues. Otherwise, nanoparticles transport occurs through 
compromised endothelial barrier or mediated by specific transport systems. Tumor tissues have an 
increased capillary permeability, which allows a high rate of nanoparticles accumulation, based on the 
“enhanced permeability and retention” (EPR) effect [13]. Nanoparticles circulating in the bloodstream 
are normally able to penetrate the tissues through a paracellular path only at restricted sites, where the 
capillaries have open fenestrations, as in the sinus endothelium of the liver, in the tumor 
neovasculature [14] or when the endothelial barrier is altered by inflammatory processes (e.g., 
rheumatoid arthritis, infections) [15].  
Surface charge is important as it determines the stability of nanoparticles, hence its propensity to 
aggregate in the bloodstream or interact with the cell membranes. The zeta potential is commonly used 
to characterize and measure the surface charge: the larger the absolute value of the zeta potential, the 
larger the charge on the surface. In a sense, the zeta potential represents an index for particle stability. 
For charged particles, as the zeta potential increases the repulsive interactions becomes larger, leading 
to stable particles, likely to have a more uniform size distribution. A nanosuspension stabilized by 
electrostatic repulsion must have a minimum zeta potential of ±30 mV [16]. This stability is important 
Materials 2010, 3 
 
1423
in preventing aggregation [17]. When a surface modifier like PEG is added, the negative zeta potential 
is lowered, although increasing the nanoparticles stability due to steric effects and hydration 
forces [18].  
Figure 1. Size of dextrin nanoparticles evaluated by (a) atomic force microscopy and (b) 
cryo-scanning electron microscopy, adapted from [19]. 
 
 
 
 
 
 
Long circulation time increases the odds for the nanoparticles to reach their target. The 
Mononuclear Phagocyte System (MPS) efficiently eliminates nanoparticles from the bloodstream, 
unless they are modeled to escape recognition. Opsonization is the process whereby a foreign 
organism or particle becomes covered with opsonins, thereby making it “visible” to phagocytic cells. 
This process typically occurs in the bloodstream and can take anywhere from a matter of seconds to 
many days to complete. Binding of opsonins onto the nanoparticle surface acts as a bridge between 
nanoparticles and phagocytes. Figure 2 shows bone marrow-derived macrophages with internalized 
polymeric nanoparticles labeled with FITC. Minimizing protein binding is the key point for 
developing long circulating time formulations. Together, these two processes—opsonization and 
phagocytosis—constitute the main blood clearance mechanism for particles larger than the renal 
threshold limit. There are no absolute rules or methods available to completely block opsonization, but 
research over the last 30 years yielded useful trends and methods to increase the blood circulation 
half-life and the effectiveness of “stealth” devices. For instance, it is well established that hydrophilic 
polymers provide steric stabilization and confers “stealth” invisibility for the body´s natural defense 
system [20]. As a general rule, the opsonization of hydrophobic particles, as compared to hydrophilic 
ones, has been shown to occur quicker, due the enhanced adsorption of blood serum proteins [21]. A 
correlation between surface charge and opsonization has also been demonstrated in vitro, neutral 
particles performing better than charged ones [22]. Therefore, a widely used method to slowdown 
opsonization relies on the use of shielding groups which can block electrostatic and hydrophobic 
interactions that help opsonins binding the nanoparticle surfaces. These groups are typically long 
hydrophilic polymer chains and non-ionic surfactants. Examples of effective shielding groups include 
polysaccharides, polyacrylamide, poly(vinyl alcohol), poly(N-vinyl-2-pyrrolidone), poly(ethylene 
glycol) (PEG), and PEG-containing copolymers such as poloxamers, poloxamines, polysorbates, and 
PEG copolymers [20,23]. Among the polymers tested to date, the most effective and most used are 
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PEG and PEG-containing copolymers, typically very flexible, highly hydrophilic and not charged, 
altogether properties lessening the protein binding. 
Figure 2. Fluorescence images obtained by confocal microscopy of murine bone 
marrow-derived macrophages (a) incubated without nanoparticles and (b) with 
FITC-containing nanoparticles (green). Nucleus stained with DAPI (blue), adapted 
from [19]. 
 
 
 
 
 
 
 
 
The high mobility of nanoparticles in the smallest capillaries allows for efficient uptake and 
selective drug accumulation at target sites [24]. Indeed, cell uptake of nanoparticles is relatively high, 
when compared to microparticles (>1 µm) [25]. Specific cell internalization can be improved by 
surface decoration with targeting ligands (peptide, sugar molecule, antibody, vitamins), which are 
recognized by target cells/tissues. The release of bioactive molecules into the cytoplasm or nucleous 
compartments can be a challenging problem. Internalized particles are initially within endosomes but 
are trafficked rapidly to lysosomes, where they are degraded enzymatically, preventing their action. To 
avoid lysosomal trafficking, smart polymers with specific chemical groups have been designed.  
Although nanogels are indeed rather promising, it must be stressed that their development as 
products for clinical applications still requires further knowledge on its physico-chemical properties, 
knowledge on the interaction with cells and tissues, nanotoxicology and safety. Generally, 
nanoparticles that have a mean diameter of approximately 100 nm, bearing a neutral and hydrophilic 
surface, exhibit prolonged blood circulation and an increased level of tumor delivery [14].  
2.3. Methods 
The self-assembly process, defined as the autonomous organization of components into structurally 
well-defined aggregates, is characterized by numerous beneficial attributes; it is cost-effective, 
versatile and facile; the process occurs towards the system’s thermodynamic minima, resulting in 
stable and robust structures. Molecular self-assembly is characterized by diffusion followed by specific 
association of molecules through non-covalent interactions, including electrostatic and/or hydrophobic 
associations (Figure 3). Individually, such interactions are weak, but dominate the structural and 
conformational behavior of the assembly due to the large number of interactions involved [26]. While 
oppositely charged polysaccharides associate readily as a result of electrostatic attractions [27], 
interactions among neutral polysaccharides tend to be weaker, or nonexistent, a modification with 
chemical entities able to trigger assembly being necessary. A convenient strategy consists on linking 
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hydrophobic grafts to e.g., a highly water-soluble polysaccharide, inducing the formation of 
nanoparticles via hydrophobic interactions. This kind of amphiphilic polymers can be constructed by 
three routes: hydrophobic chains grafted to a hydrophilic backbone, hydrophilic chains grafted to a 
hydrophobic backbone (grafted polymers) or with alternating hydrophilic and hydrophobic segments 
(block polymers). Upon contact with an aqueous environment, amphiphilic polymers spontaneously 
form self-aggregated nanoparticles, via intra- or intermolecular associations between the hydrophobic 
moieties, primarily to minimize the interfacial free energy. The important feature, from the 
physicochemical point of view, is that the molecule is able to orient itself to expose the hydrophilic 
regions to the polar environment (normally the aqueous medium) and the hydrophobic segments 
aggregates in the internal core of the material. The concentration above which the polymeric chains 
aggregate is called the critical micelle concentration or the critical aggregate concentration. Several 
strategies for the preparation of nanoparticles have been used, including direct dissolution, solvent 
evaporation/film formation, dialysis, emulsion, and co-solvent evaporation. The commercialization of 
nanodevices obtained using these technologies is limited due to the employment of potentially toxic 
organic solvents and surfactants, often not acceptable, at least for parenteral administration. For 
example, polymer based nanoparticles may be prepared by the well-known solvent evaporation 
method, in which the droplets of a nanoemulsion are composed of a volatile organic solvent in which 
the polymer is solubilized [28]. Traces of solvent are very difficult to eliminate, even using very 
sophisticated and time consuming methods such as ultradialysis, ultracentrifugation or ultrafiltration. 
In general, the currently available nanotechnologies are not able to meet the severe requirements 
enacted by the public health agencies for medicines. Therefore, there is an urgent need to develop new 
concepts and ideas to overcome these technological issues by proposing preparation procedures 
avoiding the use of organic solvents and surfactants. In this view, direct dissolution in pure water is the 
most suitable strategy to obtain nanogels [29]. 
Figure 3. Schematic representation of intermolecular interactions driving self-assembly 
processes that includes (a) electrostatic interactions and (b) hydrophobic association. 
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3. Drug Loading, Targeting and Release 
3.1. Drug loading 
Nanogels are widely used as carriers of therapeutic agents. A successful nanodelivery system 
should have a high drug-loading capacity, thereby reducing the required amount of carrier. Therapeutic 
agents can either be physically entrapped into the polymeric matrix or covalently bound to the polymer 
backbone. Polysaccharides, for instance, contain hydroxyl groups that allow direct reaction with drugs 
containing carboxylic acid function, producing ester linkages. Drugs lacking a carboxylic acid group 
require activation before the reaction takes place [30,31]. Physical drug entrapment is by far the more 
often used loading method for drug delivery applications. The best incorporation strategy for an 
efficient entrapment must be selected according to the physicochemical characteristics of the pair 
drug-carrier. Several methods have been used for drug loading, such as dialysis, nanoprecipitation, 
solvent displacement/evaporation, desolvation or direct dissolution. The encapsulation efficiency is 
different for each specific nanosystem; for example, the anti-cancer taxol is encapsulated with 100% 
and 20% efficiency on poly(lactide-co-glycolide) [32] and poly(ε-caprolactone) [33] nanodevices, 
respectively.  
The incorporation of biomolecules without compromising its bioactivity constitutes a fundamental 
goal. Physical drug loading can be performed by incorporating the drug while producing the 
nanoparticles, or by incubating a concentrated drug solution with the already formed nano-carrier. 
Drug loading and entrapment efficiency depend on the solubility in the polymeric matrix, which is in 
turn related to the polymer composition, molecular weight, drug-polymer interactions, and the 
presence of functional groups (i.e., ester or carboxyl) [34−36].  
3.2. Targeting  
Drug delivery mediated by nanoparticles can be either an active or passive process. Passive delivery 
refers to the transport through leaky capillary fenestrations, into e.g., tumor interstitium and cells, by 
passive diffusion [37]. Selective accumulation of nanoparticles and drug then occurs by EPR effect. 
Active targeting involves the use of peripherally conjugated targeting moieties, for enhanced delivery 
to a specific site, based on molecular recognition. One such approach is to surface-coat nanoparticles 
with an antibody, which can interact with its specific antigenic target cell site. According to some 
authors, antibody targeting does not increase tumor localization, instead increasing 
internalization [38,39]. The targeting moieties may help cellular uptake. Thus, long circulation times 
will allow for effective transport of the nanoparticles to the tumor site through the EPR effect, the 
targeting molecule then enabling endocytosis of the nanoparticles (Figure 4). The internalization of the 
nanoparticle is important for effective delivery of bioactive agents, especially in gene delivery, gene 
silencing, and other biotherapeutics. Sophisticated strategies to control the intracellular trafficking of 
nanoparticles are being developed [40,41]. Such advanced drug carriers can be intelligently designed 
based on the inherent properties of the target site such as pH, presence of enzymes or specific tissue 
markers. After internalization by endocytosis, nanoparticles end up in endosomes and then lysosomes, 
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where the pH values of about 5.5 (endosomes) and 4–5 (lysosomes) are found [42]. Thus, pH sensitive 
constructs may be used as a smart trigger system for drug release. 
For optimal therapeutic effect, the drug concentration must be maintained at an effective dose at the 
target site for the appropriate time-frame, with minimal dose accumulation at off-target sites. For these 
purposes, careful design of multifunctional drug carriers with nano-dimensions has become a popular 
research subject.  
Antibody fragments containing only the variable region of the antibody— that governs the 
recognition specificity—are now more commonly used for active targeting of therapeutics, avoiding 
the presence of the constant Fc effector region. This region may trigger the complement activation or 
undesirable interaction with other cells, potentially leading to premature phagocytosis of the drug 
delivery system [43]. In addition, the smaller size of antibody fragments may be an important factor in 
the development of an actively targeting nanoparticle. Antibodies, or antibody fragments, are 
conjugated either directly to the nanoparticle surface or through linker molecules such as PEG. The 
conjugation reaction is commonly carried out using carbodiimide-mediated chemistry, which creates 
stable amide bonds between carboxylic acid groups in the nano-carrier and primary amine groups, 
including lysines and the N-terminus amine, in the antibody or antibody fragment [43].  
Cell-specific ligands have been popularly employed to confer tissue- or cell-specificity to drug 
delivery systems. Specific interaction between a targeting ligand and its cellular receptor generally 
enhances the cellular uptake of nano-carriers by a mechanism called receptor-mediated endocytosis. 
Therefore, increasing the specific cellular uptake significantly improve the therapeutic efficacy 
achieved with a much lower dose [44]. A variety of targeting ligands have been used in drug delivery 
systems, including galactose and lactose to target hepatocytes, mannose for dendritic cells, RGD 
peptide to target integrins on cell surfaces and lactoferrin for bronchial epithelial. 
Figure 4. Targeting strategies for cancer therapy. Passive targeting can be achieved by 
enhanced permeation and retention, an effect involving leaky vascular structures. Active 
targeting mediated by targeting ligands specifically localizes drug carriers at desired cells 
or tissues. The decoration of the nanoparticles with ligands improves its internalization by 
endocytosis.  
Blood stream
Vascular endothelial cell
Tumor tissue
Nanoparticles with targeting moietiesNanoparticles without targeting moieties
Healthy tissue
 
Different targets may be addressed for cancer therapy purposes. Targeting angiogenesis has become 
a major area of focus. The growth of solid tumors is dependent upon the ability to generate an 
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adequate blood supply. Anti-angiogenesis approaches are effective in limiting tumor growth, the 
transformed endothelial cells of the neovasculature becoming a preferential target. Main angiogenic 
targets are the vascular endothelial growth factor receptors, αvβ3 integrins, matrix metalloproteinase 
receptors, and vascular cell adhesion molecule-1. Cell proliferation markers are another important 
target for cancer therapeutics, as many of them are highly overexpressed by certain tumor cells. 
Actively targeting nanoparticles to cell proliferation receptors may be achieved using monoclonal 
antibodies. The selection of monoclonal antibodies for cancer targeting is based on four basic criteria: 
(1) the antigen of interest is overexpressed by tumor cells, (2) the antigen participates as a principle 
component in the progression of the disease, (3) the antigen, present on the tumor cell surface must be 
stable, and (4) the antigen is expressed by a large percentage of tumor cells and a large variety of 
tumors. The most established cell proliferation targets used by actively targeting nanoparticles include 
human endothelial, transferrin and folate receptors. Targeting highly expressed antigens is a promising 
area that can ensure the elimination of malignant tumors and metastatic cells that have not become 
large enough to induce angiogenesis. 
3.3. Drug release  
The nanoparticles made of biodegradable materials allow sustained drug release over periods of 
days or even weeks. Biodegradation should not only modulate the release of drugs for a desired period 
of time, but also enable the removal of the empty device. Drug release is affected by the particle size. 
Smaller particles have a larger surface-to-volume ratio, therefore most of the drug is at or near the 
particle surface, leading to faster drug release. In contrast, larger particles allow more drug to be 
encapsulated in the inner cores, providing a slower release. Thus, control of particle size provides a 
means of tuning the drug release rates. The release mechanism can be modulated also by the molecular 
weight and the copolymer composition used. It has been shown that the higher the polymer molecular 
weight, the slower the in vitro release of drugs [37,45]. The release mechanism is a complex function 
of three main processes, i.e., drug diffusion, matrix swelling, and chemical reactivity of the 
drug/matrix. Recent studies focuses on biopolymers responsive to physiological changes such as  
pH, temperature and external stimuli such as light, that can trigger a control release of the  
therapeutic agent.  
4. Applications 
4.1. Small molecular weight drug delivery 
The sustained delivery of small drugs from polymer formulations has broad application in the 
treatment of several diseases—namely and noteworthy, the case of cancer. Biomaterial-mediated 
delivery schemes offer a unique method to deliver this kind of drugs. This section summarizes the 
polymer-based delivery systems for small drugs described in the literature, namely studies in vivo or 
using cell lines (Table 1).  
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Table 1. Nano-carriers for small molecular weight drug delivery. 
Polymer Ligand Target Cell line Drug binding Stimuli Ref 
azo-dextran aspirin -- COS-1  
simple mixing and 
irradiation with UV 
light 
UV–vis 
light 
 [46] 
carboxymethyl 
chitosan-linoleic acid 
adryamycin  
(anti-cancer) 
-- HeLa direct dissolution  --  [47] 
pullulan acetate 
adriamycin 
(anti-cancer) 
vitamin 
H 
(biotin) 
HepG2 dialysis method --  [48] 
pullulan 
acetate/sulfonamide 
adriamycin 
(anti-cancer) 
-- MCF-7 dialysis method pH  [49] 
poly[(maleilated 
dextran)-graft-(N-isoprop
ylacrylamide)] 
camptothecin 
 (anti-cancer) 
-- L929 dialysis method 
pH, 
temperat
ure 
 [50] 
poly(N-isopropylacryl 
amide)/chitosan 
camptothecin  
(anti-cancer) 
-- SW480 direct dissolution  pH  [51] 
poly[2-(N,N-diethylamino) 
ethyl 
methacrylate]-block-PEG 
cisplatin 
(anti-cancer) 
-- 
SKOV-3 
In vivo 
solvent 
displacement 
method 
pH  [52] 
poly 
(lactide-co-glycolide)-PEG 
curcumin 
(anti-cancer) 
-- 
KBM-5, Jurkat, 
DU145, 
MDA-MB-231, 
HCT116,SEG-1 
In vivo 
nanoprecipitation  --  [53] 
polylactide-co-glycolide–
PEG–folate 
docetaxel 
(anti-cancer) 
folate SKOV3 
emulsification/solv
ent diffusion 
method 
--  [54] 
poly(D,L-lactic-co-glycoli
c acid)-block-PEG 
docetaxel  
(anti-cancer) 
PSMA 
aptamer 
LNCaP nanoprecipitation --  [55] 
glycol 
chitosan-5β-cholanic acid 
docetaxel 
(anti-cancer) 
-- 
A549 
 In vivo 
dialysis method --  [56] 
poly(l-histidine)-b-PEG-f
olate (75 wt.%) and 
poly(L-lactide)-b-PEG-fol
ate (25 wt.%) 
doxorubicin 
(anti-cancer) 
folate MCF-7 
. 
dialysis method 
pH  [57] 
chitosan-poly(acrylic 
acid) 
doxorubicin 
(anti-cancer) 
-- 
HepG2 
In vivo 
direct dissolution  --  [58] 
poly(ε-caprolactone)-PEG
-poly(ε-caprolactone) 
honokiol 
(anti-inflammation) 
-- A549 direct dissolution  --  [59] 
ethylcellulose 
methylcellulose 
nimesulide 
(nonsteroid 
anti-inflammation) 
-- 
fresh human 
blood 
desolvation method --  [60] 
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Table 1. Cont. 
Polymer Ligand Target Cell line Drug binding Stimuli Ref 
poly(ethylene 
oxide)-modified 
poly(ε-caprolactone) 
tamoxifen -- 
MDA-MB-23
1 
In vivo 
solvent displacement --  [61] 
PEG-polycyanoacrylate 
paclitaxel 
(anti-cancer) 
transferr
in 
In vivo solvent evaporation  --  [62] 
poly (lactide-co-glycolide 
fumarate)/poly(lactide-co-
ethylene oxide fumarate) 
poly (lactide-fumarate)/ 
poly(lactide-co-ethylene 
oxide fumarate) 
paclitaxel  
(anti-cancer) 
-- 
HCT116 
In vivo 
dialysis method --  [63] 
PEG750-block-poly(ε-cap
rolactone-co-trimethylene
carbonate) 
paclitaxel 
 (anti-cancer) 
-- 
HeLa 
In vivo 
solvent evaporation --  [64] 
poly 
(lactide-co-glycolide)/ 
poly(ε-caprolactone)-PEG 
paclitaxel 
(anti-cancer) 
-- HeLa 
simple emulsion or 
nanoprecipitation 
method 
--  [65] 
linoleic acid/poly(β-malic 
acid) Chitosan 
paclitaxel 
(anti-cancer) 
-- In vivo 
sonication and 
dialysis method  
--  [66] 
poly(β-amino 
ester)-graft-PEG 
paclitaxel 
 camptothecin 
(anti-cancer) 
-- SKOV-3 
solvent displacement 
or dialysis method 
pH  [42] 
glycol 
chitosan-5β-cholanic acid 
protophorphyrin IX 
(photosensitizer, 
photodynamic 
therapy) 
-- 
SCC7 
In vivo 
Ex vivo 
dialysis method --  [67] 
poly(β-benzyl-l-aspartate)
-block-poly(vinylpyrrolid
one) 
prednisone 
(anti-inflammation) 
-- SW-1990 dialysis method pH  [68] 
poly (10-undecenoic 
acid-b-N-isopropylacryla
mide) 
prednisone 
(anti-inflammation) 
-- ECV304 dialysis method 
pH, 
temperat
ure 
 [69] 
cellulose-g- poly(l-lactide) 
prednisone 
(anti-inflammation) 
-- 3T3 dialysis method --  [70] 
galactosylated 
polycaprolactone- 
g-dextran 
prednisone 
(anti-inflammation) 
galactos
e 
HepG2, 3T3 
In vivo 
dialysis method --  [71] 
poly(ethylene 
oxide)-modified 
poly(ε-caprolactone) 
saquinavir  
(HIV-protease 
inhibitor) 
-- THP-1  solvent displacement --  [72] 
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Table 1. Cont. 
Polymer Ligand Target Cell line Drug binding Stimuli Ref 
water soluble chitosan 
thymol 
(anti-microbial) 
-- 
Staphylococc
us aureus 
Bacillus 
subtilis 
Escherichia 
coli 
Aspergillus 
niger 
sonication method --  [73] 
Cell line abbreviations: human cervix epithelial carcinoma cells (HeLa), human hepatocellular carcinoma 
cells (HepG2), breast carcinoma cells (MCF-7), mouse fibroblast cells (L929), human colon carcinoma cells 
(SW480), human epithelial ovarian cancer cells (SKOV-3), human chronicmyeloid leukemia (KBM-5), 
human T cell leukemia (Jurkat), prostate carcinoma (DU145), breast adenocarcinoma (MDA-MB-231), 
human colon adenocarcinoma (HCT116), human esophageal adenocarcinoma (SEG-1), prostate epithelial 
cells (LNCaP), lung cancer cells-bearing mice (A549), human colon carcinoma cells (HCT116), squamous 
cell carcinoma cells (SCC7), pancreatic cancer cells (SW-1990), human vein endothelial cells (ECV304), 
mouse fibroblasts (3T3), human monocyte/macrophage, myelomonocytic cells (THP-1) 
 
Several polymers have been exploited for the formulation of nanoparticulate carrier systems. PLA, 
PGA and PLGA have been extensively employed because of their biocompatibility, biodegradability 
and versatile degradation kinetics. For instance, haloperidol-loaded PLGA/PLA particles were 
produced by sonication or homogenization. The three most relevant properties regarding the release 
behavior were identified: polymer hydrophobicity, surface coating and particle size. The 
hydrophobicity of the polymer contributes to a reduction of the initial burst, extending the period of 
release. For example, the percentage of drug released after 1 and 35 days is respectively 46 and 70% 
for 220 nm PLA particles, as compared to 70 and 90% for PLGA particles with the same size. Coating 
the particle surface with chitosan considerably reduces the initial burst. For example, the initial burst 
registered at 1 day, using 220 nm PLGA particles, is reduced from 70 to 36% by surface coating with 
chitosan. Increasing the size of the particles also reduces both the initial burst and the rate of release. 
For example, increasing the size from 220 to 450 nm reduces the initial burst from 48 to 28%, a steady 
release of drug being observed over a 10 day time period in the later case, as compared to four days for 
the smaller particles [74].  
PEG has been extensively used to modulate the biodegradation, release profile, bloodstream 
clearance and biodistribution. For instance, nanoparticles engineered by blending PLA/PLGA 
homopolymers and PEG have been used to encapsulate betamethasone disodium 21-phosphate (BP). 
The drug release profile and the vascular circulation time-frame could be controlled by varying the 
composition/molecular weight of the polymer. The rate of in vitro BP release correlated inversely with 
the nanoparticles size and increased using PLGA instead of PLA homopolymers. Furthermore, higher 
PEG content reduces the uptake of nanoparticles by dendritic cells and accordingly improves the blood 
circulation time. Analysis of the BP organ biodistribution revealed a lower liver concentration when 
using blended nanoparticles instead of PLA nanoparticles [75]. The in vitro degradation of the 
PLGA–mPEG nanoparticles increases with the proportion of mPEG in the copolymer chains. As 
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expected, the hydrophilicity of PLGA–PEG copolymers, as evaluated by water uptake or contact angle 
measurements, was found to increase with an increase in PEG content. The higher degradation rate of 
the nanoparticles with high mPEG content may be attributed to the improved hydrophilicity, which 
apparently overrides the decreased content of cleavable ester bonds [76]. 
4.2. Protein, peptide and oligosaccharide delivery 
The oral route is the most convenient and comfortable mean for drug administration. However, the 
poor bioavailability, mainly due to the low mucosal permeability and lack of stability in the 
gastrointestinal (GI) environment, resulting in compound degradation prior to absorption, hinders a 
generalized use for proteins and peptides administration. One possible way to improve the GI uptake 
of proteins and peptides is the encapsulation in micro/nanoparticles that, while protecting from 
degradation in the GI tract, facilitate the transportation into the systemic circulation. Polymeric 
nanoparticles meet these attributes. [77,78].  
The rather large number of therapeutic proteins currently reaching the market or under clinical 
evaluation draws the urgent need for new delivery systems, using different routes of administration, 
which allow for improved stability—a main concern regarding therapeutic proteins—as well as 
controlled and targeted release. Cytokines emerge as a powerful tool for immunotherapy and 
vaccination purposes. Simultaneously, growth factors offer new opportunities for wound and tissue 
regeneration. Currently, the more effective approach to guarantee appropriate stability is protein 
pegylation. Other tools with more versatile properties are required. Colloidal polymeric carriers have 
arisen as a promising alternative for improving the transport of macromolecules: 
- proteins such as insulin [79−83];  
- cytokines [84,85] and growth factors [86];  
- peptides, e.g. RGD [87], cyclosporin A [88,89], elcatonin [90,91], vasoactive intestinal 
peptide [92], anti-cancer glycoprotein lectin A-chain [93] and a caspase inhibitor peptide [94]  
- oligossacharides, such as heparin [95−97].  
These recent reports on the development of new protein delivery systems are discussed below. 
The cationic nature of chitosan makes it an interesting polymer for the association with and delivery 
of labile negatively charged macromolecules. Several studies addressed the nasal delivery of insulin 
with chitosan nanoparticles [98,99]. The potential of protonated chitosan has been enforced by the 
recognition of its ability to trigger the opening of tight junctions, thereby facilitating the transport of 
macromolecules through the epithelium. Indeed, it has been demonstrated that nanoparticles can 
enhance the oral bioavailability of encapsulated therapeutic proteins. For this purpose, a 
nanoparticulate system composed of trimethyl chitosan (TMC) and cysteine (Cys), attempting to 
combine the mucoadhesion and permeation enhancing effects, was tested. When reaching the small 
intestine, the positively charged nanoparticles—which interact electrostatically with the mucous 
layer—induce transient loosening of the tight junctions. The free thiol groups on TMC-Cys allow the 
formation of disulfide bonds with the cysteine-rich mucin. Therefore, a closer and prolonged action on 
the tight junctions favors both the paracellular transport of the insulin and nanoparticle internalization 
by enterocytes. Oral administration of insulin-loaded TMC-Cys nanoparticles led to notable 
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hypoglycemic effects, which lasted until eight hours post-administration, with a maximum blood 
glucose depression of 35% [100].  
In cytokine immunotherapy, a suitable delivery system that ensures slow-release of cytokines is 
required, the short in vivo half-life of these molecules ruins its therapeutic eﬃcacy, while causing 
severe systemic toxic effects. Recombinant murine IL-12 (rmIL-12) was successfully incorporated into 
cholesterol-bearing pullulan (CHP). The subcutaneous injection of the CHP/rmIL-12 complex led to a 
prolonged elevation of IL-12 concentration in the serum. Repetitive administrations of the complex 
induced drastic growth retardation of reestablished subcutaneous fibrosarcoma, without causing 
toxicity [84].  
Bone morphogenetic proteins (BMPs) are cytokines with a strong ability to promote new bone 
formation. Elastin-like nanoparticles, created by thermoresponsive self-assembly, were developed for 
the combined release of bone morphogenetic protein-2 (BMP-2) and bone morphogenetic protein-14 
(BMP-14). These BMPs could be encapsulated efficiently into the elastin-like particles and delivered 
in a sustained way for 14 days. The activity of the growth factors was retained and increased 
bioactivity on C2C12 cells was observed following the combined release of BMP-2 and BMP-14 [86].  
The development of peptides and proteins acting on the central nervous system is drastically 
hindered by the blood-brain barrier (BBB). The surface engineering of nanoparticles with lectins 
opened a novel pathway for the delivery of drug-loaded biodegradable nanoparticles into the brain, 
following intranasal administration. The neuroprotective Vasoactive Intestinal Peptide (VIP) was 
efficiently incorporated into PEG-PLA nanoparticles surface-modified with wheat germ agglutinin. 
This formulation allows a more effective delivery, as compared with the intranasal application of the 
soluble peptide. This is partially attributed to the higher affinity of the wheat germ 
agglutinin-conjugated nanoparticles to the olfactory mucosa, rather than to the respiratory one [92]. 
The peptide Z-DEVD-FMK, a caspase inhibitor, reduces vulnerability of the neuronal cells. The 
clinical application is hindered by its inability to cross the BBB and diffuse into the brain tissue. Thus, 
chitosan-PEG nanospheres bearing the OX26 monoclonal antibody (affinity for the transferrin 
receptor) have been designed, which trigger the receptor-mediated transport across the BBB. An 
important amount of nanoparticles were located in the brain, outside of the intravascular compartment. 
Hence, OX26 functionalized chitosan-PEG nanoparticles are promising carriers for the transport of the 
anti-caspase peptide into the brain [94].  
The peptide Arg–Gly–Asp (RGD) draws much attention for tumor therapy applications, because it 
specifically binds αvβ3 integrins, expressed by angiogenic endothelial cells. Attempting to overcome 
the short half-lives of several systemic anti-angiogenic peptides, a carrier for the RGD peptide was 
produced, using self-assembled nanoparticles of hydrophobically modified glycol chitosan (HGC). A 
high RGD loading efficiency was achieved (over 85%), and the system showed prolonged and 
sustained release for about 1 week. The RGD loaded-HGC nanoparticles displayed anti-angiogenic 
activity, markedly suppressing bFGF (inducer of angiogenesis) as well as preventing microvessel 
formation. Due to the sustained RGD peptide delivery, RGD-HGC nanoparticles significantly 
decreased tumor growth and microvessel density, improving the effect obtained injecting the free RGD 
peptide, either intravenously or intratumorally [101].  
Limitations in the management of extraocular diseases include the inability to provide long-term 
extraocular drug delivery without compromising intraocular structures. Since the cornea has negative 
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charge, mucoadhesive polymers can interact with the extraocular structures, increasing the 
concentration and residence time of immunosuppressive peptide cyclosporin A (CyA). The 
hydrophobic peptide, CyA, was associated to chitosan nanoparticles. In vivo experiments showed that, 
following topical instillation of CyA-loaded chitosan nanoparticles to rabbits, it was possible to 
achieve therapeutic concentrations in external ocular tissues (i.e., cornea and conjunctiva) during at 
least 48 hours, while maintaining negligible or undetectable CyA levels in inner ocular structures (i.e., 
iris/ciliary body and aqueous humor), blood and plasma [88].  
Pulmonary drug delivery for both local and systemic action has many advantages over other 
delivery routes. The lungs offer a large surface area, a rather thin absorption barrier, low enzymatic 
metabolic activity and slow mucociliary clearance. Therefore, PLGA nanospheres, surface-modified 
with chitosan, were developed and used for pulmonary delivery of elcatonin, a calcitocin derivative 
(formulated for the management of several bone-related diseases). The coated nanospheres were 
eliminated from the lungs at slower rate. Loaded elcatonin reduced blood calcium levels to 80%, 
exhibiting a prolonged pharmacological action, for over 24 hours. The results showed that the 
nanospheres adhered to the bronchial mucus and lung tissue, allowing the sustained drug release at the 
adherence site. Additionally, flexible chitosan molecules on surface of the nanospheres enhanced the 
drug absorption, maybe by opening the intercellular tight junctions [90]. 
The macromolecular drug heparin, a sulfated natural glycosaminoglycan, is vulgarly used as an 
injectable anticoagulant [97]. Recently, heparin has been loaded into nanoparticles of chitosan and 
hyaluronic acid, developed for anti-asthmatic therapy applications. The nanosystems were stable in 
phosphate buffered saline pH 7.4 for at least 24 hours, and released 10.8% of unfractionated heparin 
within 12 hours of incubation. Fluorescent heparin-loaded nanoparticles were effectively internalized 
by rat mast cells. Ex vivo experiments, conducted to evaluate the capacity of heparin to prevent 
histamine release in rat mast cells, indicated that the free or encapsulated drug exhibited the same 
dose–response behavior [95]. Intracellular delivery of heparin by chitosan-g-PEG/heparin 
polyelectrolyte complexes has also been used to trigger caspase activation and consequently promote 
apoptotic death of cancer cells [96].  
4.3. Vaccine delivery 
The recent developments in nanotechnology increased considerably the interest in nanoparticulate 
systems as a platform for the delivery of antigens. The key challenges are the induction of a potent and 
broad (both humoral and cellular) antigen-specific immune response, capable of protecting from 
infection (sterilizing vaccination) and/or disease (therapeutic vaccination) and finally, to develop 
effective immunity after a single injection of the vaccine. Particulate delivery systems mimic 
pathogens that are commonly recognized, phagocytosed, and processed by professional 
antigen-presenting cells (APCs). APCs, such as dendritic cells and macrophages, represent the 
sentinels of the immune system and orchestrate antigen-specific T cell-mediated immune responses. 
Activated APCs migrate to regional lymph nodes where they present the antigen to T cells, thereby 
triggering cellular and humoral immunity. Most organisms are detected and destroyed within hours by 
defense mechanisms, which are not antigen-specific and do not require any prolonged period of 
induction. These are the mechanisms of innate immunity. Only when the infectious agent is capable of 
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breaking this early line of defense, an adaptive immune response will develop. This includes 
generation of antigen-specific effector cells that specifically target the pathogen, secretion of 
antibodies (B cells), direct cytotoxic activity (T cells), or secretion of immunological mediators and 
effector molecules such as cytokines and chemokines. Although most of these effector cells will die 
within 10–14 days after infection, some cells will survive, as highly reactive plasma cells (B cells) or 
memory cells (B and T cells), and prevent subsequent infection by the same microorganism. Along 
with long-lasting antibodies against a specific pathogen, the induction of memory cells is the final goal 
of preventive vaccination.  
Immunity against an infectious agent by vaccination can be achieved in various ways, normally 
including several components. Firstly, the antigen itself can be a synthetically produced peptide 
representing an epitope of a pathogen protein. It can also be the full-length protein carrying several 
epitopes that are recognizable by B and T cells. Such full-length proteins can be secreted from the 
pathogen or produced synthetically or recombinantly. Vaccine development has also focused on 
experimental vaccines where the gene encoding a particular protein is fused into a DNA or RNA 
plasmid. Secondly, the formulation or delivery system varies considerably from one vaccine to 
another. DNA and some protein vaccines can be administered in solution without adjuvant 
enhancement of the immune response. Today, still many of the most potent vaccines are given as a live 
attenuated or killed form of the particulate microorganism. A unique property, especially of live 
vaccines, is that they often induce strong T cell responses. This property is very much missed by 
protein or peptide vaccines administered with those adjuvants in general use today, e.g., aluminum 
salts. Thus, there is an urgent need for the development of potent and safe antigen-delivery systems. 
The development of nanoparticulate vaccines is also motivated by safety concerns, e.g., to avoid the 
risk of infection induced by live attenuated vaccines and to suppress the excessive inflammation that is 
frequently caused by the use of Freund’s adjuvant or aluminum salts adjuvant. 
Cancer vaccines are a promising approach for anti-cancer therapy, as fewer side effects are induced 
than with other therapies and, more importantly, there is an opportunity for developing long-term 
immunity [102]. In contrast to general medicines, which are directly targeted to specific molecules, 
cancer vaccines initiate a cascade of antigen specific immune responses against antigen-expressing 
tumor cells. Activating the immune system to trigger a specific response sufficient for the eradication 
of tumor cells, however, is a major challenge in the development of cancer immunotherapy.  
A possible key for the successful development of new generation of vaccines may lie in the use of 
targeted delivery systems (Table 2). Nanoparticulate systems are particularly well suited for the 
delivery of antigens specifically to DCs, inducing the subsequent activation of T cell immunity, given 
its ability to permeate the lymphatic draining system and reach DCs in the lymph nodes. However, 
antigen delivery to—and activation of—DCs is a complex problem, involving antigen transport to 
DC-rich areas, DC binding and eventually antigen uptake, and antigen processing and presentation. 
Before an antigen can be processed and presented by DCs, the biomaterial vehicle itself must be 
internalized by DCs. Immature DCs internalize exogenous solutes, particles, and necrotic or apoptotic 
cells through macropinocytosis, receptor-mediated endocytosis and phagocytosis [103]. Several 
studies confirmed that DCs can internalize polymeric nanoparticles [104], the internalization 
mechanism being partially controlled by altering the properties of the biomaterial vehicle, namely the 
size [105]. Macropinocytosis is used to internalize extracellular fluid and smaller solutes such as 
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macromolecules [103] and particularly small nanoparticles (< 50 nm), whereas phagocytosis occurs 
when larger nanoparticles (> 500 nm) are taken up [106,107]. DCs also use surface receptors to 
endocytose ligands with a terminal sugar such as mannose [108]. Thus, both the physicochemical and 
biochemical character of biomaterial vehicles can be adjusted to tailor DC uptake. 
Following internalization, the biomaterial vehicle must then release the antigen intracellularly, in a 
manner that will enable processing by MHC class I, class II, or both (cross-presentation) pathways. 
The delivery of exogenous antigen inducing cellular immunity through the MHC class I pathway can 
be a challenging problem, as internalized particles are initially within endosomes but are trafficked 
rapidly to lysosomes, where they are degraded enzymatically, preventing the antigen from being 
processed and presented. To avoid lysosomal trafficking, smart polymers have been designed. These 
polymers are broken down inside the endosomes, due to the presence of acid-degradable acetal bonds, 
triggering the disruption of the endosomes in a pH-dependent fashion. The process occurs as follows: 
at pH 7.4 the polymers are PEGylated (“masked”); however, after endocytosis the acid labile linker is 
hydrolyzed and the polymer backbone becomes de-PEGylated (“umasked”) and membrane-disruptive, 
causing endosomal disruption. The PEGs may be conjugated to the backbone via both acid-degradable 
linkages and disulfide bonds. These polymers release oligonucleotides and peptides into the cytoplasm 
as the endosome is acidified, avoiding the lysosomal fusion; releasing antigen into the cytoplasmic 
compartment enables processing by MHC class I instead of the MHC class II pathway [109]. This 
strategy exemplifies how smart biomaterials may be engineered as to overcome biological barriers and 
control the intracellular biodistribution.  
Targeting lymph-node DCs, rather than peripheral ones in the skin for example, offers many 
theoretical advantages [110]. The avoidance of premature antigen presentation, because DCs in lymph 
nodes are already at the site of antigen presentation, is one potential benefit. For successfully targeting 
lymph-node-resident DCs, it is crucial to engineer biomaterial vehicles that can be readily taken up 
into lymphatic vessels after subcutaneous or intradermal injection, being then retained in draining 
lymph nodes. It has been well-established that particle size is among the most crucial factors for 
lymphatic uptake from the interstitial space [111].  
As the mucosal route of administration (e.g., intranasal, oral) is considered a simple, safe, 
efficacious, non-invasive and less expensive method to deliver antigens, novel strategies for the 
achievement of safe and effective immunization strategies are under investigation regarding the routes 
of vaccination. Mucosal immunization is an attractive alternative to parenteral vaccination; using the 
appropriate delivery system it is possible to stimulate both mucosal and systemic immune 
responses [112]. Mucosal vaccination offers also several benefits over parenteral route, including ease 
of administration, reduced side effects, possibility of self-administration and, especially in developing 
countries, reduced risk of the unwanted spread of infectious agents via contaminated syringes. 
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Table 2. Polymeric nanoparticles for vaccine delivery. 
Polymer Antigen Remarks route Ref 
poly-l-lysine 
coated 
polystyrene 
particles 
sOVA-C1 plasmid 
Particles of different sizes may target different 
APCs. 
intradermal  [113] 
poly-(ε-caprolacto
ne) 
-poly(lactide-co- 
glycolide) 
diphtheria toxoid 
Correlations between polymer characteristic (e.g., 
hydrophobicity ) and route of administration, 
indicate that such characteristics can have 
interesting implications in immune responses. 
intranasal 
intramuscular 
 [114] 
methoxyPEG– 
poly(lactide-co- 
glycolide) 
recombinant 
hepatitis B surface 
antigen (HBsAg) 
Delivery of HBsAg encapsulated within a 
nanoparticle is a superior way for generating faster 
immune responses, as compared to the 
non-encapsulated counterpart. 
intraperitone
al  
 [115] 
poly lactic 
acid-PEG 
recombinant 
hepatitis B surface 
antigen (HBsAg) 
Different compositions of PLA and PEG polymers 
were synthesized to stabilize the antigen. A 
comparison of their efficacy in the generation of an 
effective immune responses is shown. 
nasal  [5]  
poly(γ-glutamic 
acid)-graft-L-phen
ylalanine 
japanese encephalitis 
(JE) vaccine 
A single dose of JE vaccine with nanoparticles 
enhanced the neutralizing antibody titer.  
intraperitone
al  
 [116] 
poly(γ-glutamic 
acid)-graft-l- 
phenylalanine 
influenza 
hemagglutinin (HÁ) 
vaccine 
Subcutaneous immunization with a mixture of HA 
vaccine and nanoparticles induced higher 
mononuclear cell proliferation and production of 
IFN-γ, IL-4, and IL-6 upon HA restimulation. 
subcutaneous  [117] 
poly 
(d,l-lactide-co-gly
colide)–polyethyle
neimine 
DNA encoding 
Mycobacterium 
tuberculosis latency 
antigen Rv1733c 
The polyplexes were able to mature human 
dendritic cells and stimulated the secretion of 
cytokines, comparable to levels observed after 
lipopolysaccharide stimulation. 
intramuscular
ly 
endotracheal 
 [118] 
hydrophobically 
modified 
poly(γ-glutamic 
acid) 
gp120 (human 
immunodeficiency  
virus -1) 
The protein-encapsulated nanoparticles induced 
cytotoxic T lymphocyte. Efficient uptake by 
immature dendritic cells (DC) and induction of DC 
maturation was observed. 
intranasal  [25]  
chitosan 
DNA vaccine 
encoding mite dust 
allergen Der p 2 
(Der p 2-pDNA) 
Chitosan-DNA nanoparticles can generate a higher 
level expression of gene in vivo, therefore can 
preferentially activate specific Th1 immune 
responses thus preventing subsequent sensitization 
of Th2 cell-regulated specific IgE responses. 
oral  [119] 
chitosan 
plasmid DNA 
encoding surface 
protein of Hepatitis 
B virus 
(pRc/CMV-HBs(S)) 
Administration of nanoparticles resulted in serum 
anti-HBsAg titer and induced sIgA titre in mucosal 
secretions. Chitosan nanoparticles were able to 
induce humoral mucosal and cellular immune 
responses. 
nasal   [120] 
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Table 2. Cont. 
Polymer Antigen Remarks route Ref 
chitosan 
DNA plasmids 
expressing different 
M. tuberculosis 
epitopes 
Chitosan nanoparticles protect DNA from 
degradation by nucleases, induce dendritic cells 
maturation and increased IFN-γ secretion from T 
cells. 
pulmonary  [121] 
chitosan 
pcDNA3-VP1, 
encoding VP1, 
major structural 
protein of 
coxsackievirus 
(CVB3) 
Nasal administrated chitosan–DNA produced 
higher levels of serum IgG and mucosal secretory 
IgA. Strong cytotoxic T lymphocyte activities 
helped to effectively eliminate CVB3 viruses. 
intranasal  [122] 
low molecular 
weight chitosan 
(LMWC) 
plasmid DNA 
encoding human 
cholesteryl ester 
transfer protein 
C-terminal fragment 
(CEPT) 
LMWC had lower binding affinity to DNA, but 
mediated higher transfection efficiency. Polyplexes 
could elicit significant systemic immune responses, 
modulate the plasma lipoprotein profile and 
attenuate the progression of atherosclerosis. 
intranasal [123] 
mono-N-carboxy
methyl chitosan 
(MCC) 
N-trimethyl 
chitosan (TMC) 
tetanus toxoid 
Surface charge and particle size exert an important 
influence in the production of an enhanced immune 
response. 
intranasal  [112] 
 
4.4. Gene delivery 
Nucleic acid-based biopharmaceuticals, such as pDNA, oligonucleotides (ODNs) and short 
interfering RNA (siRNA), are potential pioneering materials to cope with various incurable diseases. 
Cationic polymers condense DNA into nanosized polymer/DNA complexes (polyplexes), by a 
self-assembling process, consisting on the electrostatic interaction of the positively charged polymer 
with the negatively charged DNA. Polyplexes may interact with the negatively-charged cellular 
membrane, being internalized via endocytosis. In the intracellular environment, the polyplexes are 
normally located in endosomes that become acidified and finally fuse with lysosomes. In this case, 
DNA is prone to degradation by lysosomal enzymes. In order to transfer their DNA cargo successfully 
to the nucleus, polyplexes must escape from the endosome. After endosomal escape, polyplexes are 
located in the cytoplasm, ready to unpack DNA and deliver it to a suitable site near the nucleus or in 
the nucleus. Finally, after the DNA translocation into the nucleus, gene expression must occur. The 
low efficiency of polymer-mediated gene delivery may be due to the lack of mechanisms to overcome 
the physiological barriers. Cationic polymers need to have multiple functions to overcome these 
barriers, such as good DNA binding ability to condense DNA into polyplexes, high buffer capacity to 
induce endosomal escape and efficient intracellular vector unpacking to release DNA [124]. Therefore, 
understanding of the correlations between polymeric functionalities and gene delivery properties is 
important for the rational design of efficient cationic polymeric vectors.  
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RNA may be advantageously used instead of DNA for gene delivery purposes. First, the delivery 
target is the cytosol, not the nucleus. Cytosol delivery is by far easier and more efficient than nucleus 
delivery. Quite recently, siRNA has emerged as a more powerful therapeutic genetic agent [125]. High 
sequence specificity and relatively small dose requirement of siRNA make it even more attractive. The 
most challenging hurdles are serum instability during circulation in the bloodstream [43], poor cellular 
uptake, and limitation in targeted delivery to specific tissues or cells. To address such problems, 
natural or synthetic polymeric delivery systems have been used. The natural polymers investigated for 
gene therapy include chitosan, collagen, gelatin and their modified derivatives [126] (Table 3). Among 
the synthetic polymers, poly(l-lysine) or polyethylenimine and their analogs have been widely 
used [127] (Table 4). Other synthetic alternative nano-carriers have been synthesized, engineered with 
linkages envisaging physiological degradation (Table 5). Specific targeting moieties may be 
conjugated to confer tissue specificity. Chitosan has emerged as an alternative non viral gene delivery 
system. The transfection efficiency of chitosan/DNA complexes is dependent on several factors: 
chitosan degree of acetylation and molecular weight [128−130], amine/phosphate ratio of 
chitosan/DNA complexes [131,132], serum concentration, pH [128] and cell type [133,134]. Chitosan 
derivatives (glycol, o-carboxymethyl, trimethylated, thiolated and 6-N,N,N-trimethyltriazole chitosan) 
including hydrophobic modifications (deoxycholic acid, 5β-cholanic acid, N-acylated chitosan) have 
been used to overcome the limited chitosan solubility and improve transfection efficiency. Concerning 
biodegradation, chitosan is degraded into oligomers by lysozyme, and then further degraded by 
N-acetyl-glucosaminidase, in animal cells. Both of these enzymes are present in the 
endosomal/lysosomal vesicles, thus the degradation and release of pDNA will start immediately after 
endocytosis of the chitosan polyplexes. Additionally, lysozyme is present at inflammation sites, which 
allow specific release. The chitosan cytotoxicity is lower than that of polyethylenimine, supporting the 
suggestion that chitosan may be a nontoxic alternative to polyethylenimine [135].  
Polyethylenimine (PEI), often considered the gold standard of gene transfection, is one of the most 
prominent examples of cationic polymers capable of gene transfection. The transfection efficiency of 
PEI has been related to the buffering effect exerted by the amines, with different pKa values, over a 
wide range of pH. This buffering ability gives PEI an opportunity to escape the endosome (proton 
sponge effect) [136]. PEI, as poly-L-lysine (PLL), often show a relatively high cytotoxicity and, 
depending on the ionic strength, a tendency to aggregate and precipitate [137]. The conjugation with 
PEG prevents the inter-particular aggregation of the complexes, increasing their stability [138,139]. 
The non-degradability of non-viral carriers may represent a major limitation, since it implies they 
are not removed by physiological clearance systems and, therefore, can possibly accumulate within 
cells or tissues, eliciting further cytotoxicity. The backbone linkages of most polymeric gene carriers 
consist of a –C–C– bond or amide bond, which are not degraded in physiological solutions. 
Additionally, the biodegradation of the polymer may provide an extra tool to release the plasmid DNA 
into the cytosol. In an effort to develop alternative non-toxic and effective nano-carriers modified 
polymers, with functional groups labile under physiological conditions (ester, phosphorus or disulfide 
bonds), were produced. The use of the disulfide bond as bioreducible linker has received much 
attention in recent years [140,141]. The disulfide bond can be cleaved intracellularly by reducing 
enzymes such as glutathione reductase and sulfhydryl components like glutathione. Since the 
concentration of these reducing species is much higher in the cytoplasm than in plasma (intracellular 
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versus extracellular glutathione concentration 0.5–10 mM versus 2–20 μM) [142], the disulfide bond is 
relatively stable in the extracellular environment, but rapidly degradable inside the cells, due to the 
higher amounts of thiols. To achieve high efficiency of polymer-mediated gene delivery, endosomal 
escape is required. This mechanism can be improved with the addition of chloroquine or 
membrane-active peptide [143]. An alternative method to promote endosomal lysis consists in 
engineering the carrier cationic polymers with histidine or imidazole groups. The transfection 
enhanced activity is assigned to the imidazole heterocycle, which displays a pKa around 6, thus 
possessing a buffering capacity at the endolysosomal pH [144]. 
Several examples of polymeric nanogels developed for gene therapy are given below. 
Anti-angiogenic therapy has become an important route for cancer treatment. Among factors that 
regulate angiogenesis, the vascular endothelial growth factor (VEGF) appears to be the most critical 
regulator of tumor-induced angiogenesis, which is essential for the survival of rapidly proliferating 
cancer cells and sustained growth of tumor. For this purpose, a PEG-conjugated VEGF-siRNA was 
complexed with polyethylenimine. Intravenous as well as intratumoral administration of these 
polyplexes significantly inhibited VEGF expression at the tumor tissue, suppressing tumor growth in 
an animal tumor model, without showing any detectable inflammatory responses in mice [145].  
Table 3. Natural-based polymers for gene delivery. 
Polymer 
Therapeutic 
agent 
Ligand Remarks Ref 
chitosan 
sense or antisense 
oligodeoxynucleotides 
(ODNs) against malarial 
topoisomerase II gene 
-- 
Antisense-nanoparticles demonstrate a significant 
higher inhibition of human malaria parasite, as 
comparison with sense-nanoparticles and free 
ODNs. More easily dissociated complexes mediate 
a faster onset of action. 
 [146] 
folate-N-trimethyl 
chitosan 
pDNA folate 
Folate conjugation increased intracellular uptake , 
transfection efficiency and induce endosomal 
escape. 
 [147] 
folic acid-chitosan pDNA (pVR1412) folate 
Nanoparticle with positive zeta potentials interact 
with the cell membrane allowing their endocytosis. 
 [148] 
galactosylated 
6-amino-6-deoxyc
hitosan 
pDNA (pCMV-Luc) galactose 
The increase of transfection eﬃciency of Gal-6ACT 
was therefore likely due to improvements in 
intracellular traﬃcking and not due to the increase 
of cellular uptake., 
 [149] 
chitosan/ 
hyaluronic acid 
pDNA(pEGFP-C1, 
pβ-gal) 
hyaluron
an 
Polyplexes were able to provide high transfection 
without affecting cell viability, entering the corneal 
epithelial cells by CD44 receptor–mediated 
endocytic uptake.  
 [150] 
mannosylated 
chitosan 
pDNA (pGL3-Luc) mannose 
Cellular uptake mediated by mannose recognition. 
Reduced toxicity and high transfection efficiency. 
 [151] 
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Table 3. Cont. 
Polymer 
Therapeutic 
agent 
Ligand Remarks Ref 
chitosan –IL-1Ra 
folate- IL-1Ra- 
Chitosan 
IL-1Ra plasmid DNA folate 
Folate-chitosan-DNA nanoparticles containing the 
IL-1 Ra gene prevent bone damage and 
inflammation in rat adjuvant-induced arthritis model 
that overexpress folate receptors. 
 [152] 
PEG-Chitosan 
pDNA (pRE-luciferase; 
pREP4;pCMV- 
luciferase) 
transferri
n 
KNOB 
protein 
The transfection efficiency was much impressive 
with KNOB (130-fold improvement), in HeLa cells. 
Chitosan exhibited limited buffering capacity. The 
clearance of the PEGylated nanoparticles was 
slightly slower than that of the unmodified 
nanoparticles. 
 [153] 
chitosan plasmid pGL3-Luc -- 
Polyplexes are endocytosed and possibly released 
from endosomes due to swelling of both lysosomes 
and polyplexes, causing the endosome rupture. 
 [154] 
chitosan 
pDNA 
(pAAV-tetO-CMV-mEp
o and pCMVβ) 
-- 
Oral gene therapy was efficient in delivering genes 
to enterocytes. 
 [155] 
thiolated chitosan pDNA (pEGFP-N2) -- 
Improved gene delivery in vitro as well as in vivo. 
The extended pDNA release and subsequent gene 
expression were achieved by oxidation of 
introduced thiol groups to crosslink the thiolated 
chitosan. 
[156] 
quaternized 
(trimethylated) 
chitosan oligomer 
pDNA (pEGFcp1-GFP) -- 
Transfection efficiency decreases increasing the 
degree of quaternization. The polymer effectively 
transfers the GFP gene into cells both in vitro and 
in vivo. 
 [157] 
6-N,N,N-trimethyl
triazole chitosan 
pDNA (EGFP-N1 -- 
The presence of the trimethyltriazole group led to 
significantly increased cellular uptake, which 
resulted in higher transfection efficiency in HEK 
293 and MDA-MB-468 cells. 
[158] 
methoxy 
PEG–PEI–chitosan  
pDNA (pVRfat-1) -- 
The mPEG increased the slow-releasing ability and 
water solubility, while PEI improved the 
transfection efficiency.  
 [159] 
chitosan/ 
poly(γ-glutamic 
acid) 
pDNAs (pEGFP-N2, 
pGL4.13 and 
pEGFP-N2) 
-- 
The incorporation of γ-PGA in the chitosan 
nanoparticles facilitates the dissociation of chitosan 
and DNA, increasing transfection efficiency. 
Trypsin-cleavable proteins in cellular membrane 
affect internalization of polyplexes. 
 [160] 
methylated 
collagen 
pDNA (pRELuc) -- 
Methylated collagen improved DNA binding 
ability and the stability of the complexes at 
physiological conditions, as compared with 
unmodified native collagen.  
 [161] 
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Table 3. Cont. 
Polymer 
Therapeutic 
agent 
Ligand Remarks Ref 
cationized gelatin 
plasmid DNA of 
transforming growth 
factor-βR (TGF-βR) 
siRNA expression 
vector 
-- 
The injection of polyplexes significantly decreased 
the level of TGF-βR and α-smooth muscle actin 
over-expression, the collagen content of mice 
kidney, and the fibrotic area of renal cortex, in 
contrast to free plasmid DNA injection. 
 [162] 
PEG–modified 
thiolated gelatin 
pDNA (EGFP-N1) -- 
Nanoparticles released encapsulated plasmid DNA 
in response to varying concentrations of 
glutathione. 
 [163] 
 
Multidrug resistance remains a major barrier to the success of anti-cancer chemotherapy [164]. 
Overexpression of drug efflux transporters, such as P-glycoprotein, enables cancer cells to develop 
resistance to multiple anti-cancer drugs. A novel approach to overcome drug resistance consist in using 
the siRNA-mediated silencing the expression of the efflux transporter. Because P-glycoprotein plays 
an important role in the physiological regulation of endogenous and xenobiotic compounds, it is 
important to deliver the P-glycoprotein targeted siRNA (associated with anti-cancer drugs) specifically 
to tumor cells. Recent studies have shown that nanoparticles formulated with 
poly(D,L-lactide-co-glycolide) and polyethyleneimine result in sustained siRNA delivery and efficient 
gene silencing Nanoparticles were surface functionalized with biotin for active tumor targeting. In vivo 
studies, in a mouse model of drug-resistant tumor, demonstrated significantly greater tumor growth 
inhibition following treatment with biotin-functionalized nanoparticles encapsulating both paclitaxel 
and P-glycoprotein targeted siRNA. Remarkably, this effect was obtained using a paclitaxel dose 
ineffective in the absence of gene silencing [165]. Recently, dual nanogels, for co-delivery of drug and 
gene, were synthesized and evaluated as carriers [166,167]. Inhibition of ret/PTC1 oncogene, in the 
papillary thyroid carcinoma, has been achieved after administration of siRNA using chitosan-coated 
biodegradable poly(isobutylcyanoacrylate) nanoparticles. The nanoparticles protect the ret/PTC1 
siRNA from in vivo degradation, leading to significant tumor growth inhibition after intratumoral 
administration, correlated to reduced ret/ PTC1 levels [168]. 
A novel approach for the control of inflammation in rheumatoid arthritis was reported. The strategy 
consisted in using chitosan/siRNA nanoparticle to silence the TNF-α expression in peritoneal 
macrophages. The nanoparticles, containing an unmodifed anti-TNF-α DsiRNA, mediated TNF-α 
knockdown (~66%) in primary peritoneal macrophages, in vitro. Histological analysis of joints 
revealed minimal cartilage destruction and inflammatory cell infiltration in anti-TNF-α-treated mice. 
Therefore, nanoparticle-mediated TNF-α knockdown in peritoneal macrophages may be a method to 
reduce local and systemic inflammation, and a novel strategy for arthritis treatment [169]. Other 
approach hypothesized that IL-1Ra (Interleukin-1 receptor antagonist) gene delivery can defend 
against inflammatory bone turnover, in rheumatoid arthritis patients. As compared to naked DNA and 
chitosan–DNA, folate–chitosan–DNA nanoparticles were less cytotoxic and enhanced IL-1Ra protein 
synthesis in vitro, offering a better protection against inflammation and abnormal bone metabolism in 
vivo [152].  
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Table 4. Polyethylenimine (PEI) and poly(l-lysine) (PLL)-based polymers for gene delivery. 
Polymer 
Therapeutic 
agent 
Ligand Remarks Ref 
PEG-PEI 
(NanoGelTM) 
antisense 
oligonucleotide (ODN) 
targeting the mdr1 gene 
transferrin 
insulin 
Transport efficacy across the blood-brain 
barrier is increased by modification with 
transferrin or insulin. Improvement of 
ODN accumulation in the brain (15 fold). 
 [9] 
lactoferrin-PEI pDNA lactoferrin 
Selectivity for bronchial epithelial cells. 
Lower cellular toxicity of polyplexes and 
higher transfection efficiency (5-fold 
higher), as compared with PEI/pDNA 
complexes. 
 [170]  
RGD-PEG-PEI 
siRNA inhibiting 
vascular endothelial 
growth factor 
receptor-2 
RGD 
Selective tumor uptake, siRNA 
sequence-specific inhibition of protein 
expression within the tumor and inhibition 
of both tumor angiogenesis and growth 
rate. 
 [44]  
PEI-g-PEG-RGD 
 
pDNA (pCMV-sFlt-1) 
 
RGD 
 
Efficient inhibition on proliferation of 
endothelial cells that expressed sFlt-1 
predominantly bound to exogenous VEGF 
and blocked the binding of VEGF to the 
full-length Flt-1 receptor. 
 [171]  
siRNA-PEG-LHRH/ 
PEI 
siRNA (VEGF-vascular 
endothelial growth 
factor) 
luteinizing 
hormone- 
releasing 
hormone 
(LHRH) 
Enhancement of cellular uptake, as 
compared to those without LHRH, 
resulting in increased VEGF gene 
silencing efficiency via receptor-mediated 
endocytosis. 
 [172]  
EGF-PEG-PEI pDNA (pCMVLuc) 
epidermal 
growth factor 
(EGF) 
peptides 
EGF-containing polyplexes were 10- to 
100-fold more efficient than polyplexes 
without EGF. 
 [173]  
PEI pDNA 
Peptide 
(NL4-10K) 
Polyplexes displayed no toxicity in 
neuronal cells. Enhancement of gene 
expression (up to 1000-fold) and 
transfection efficiency (59-fold higher), in 
dorsal root ganglia, compared to 
nontargeting polyplexes. 
 [174]  
PEI-g-Clenbuterol pDNA (pCMVLuc) 
β2-adrenocept
or 
(clenbuterol) 
Specific cellular uptake into alveolar 
(transfection efficiency 14-fold higher than 
for unmodified PEI) but not bronchial 
epithelial cells. 
 [175]  
folate–PEG–PEI 
pDNA (pCMV-Luc or 
pcDNA/rev-caspase-3) 
folate 
Higher transfection efficiency than other 
commercially available transfection 
agents. 
 [176]  
     
Materials 2010, 3 
 
1444
Table 4. Cont. 
Polymer 
Therapeutic 
agent 
Ligand Remarks Ref 
PEI-PEG-Fab’ pDNA (pCMVLuc) 
anti- glutamic 
acid 
decarboxylas
e (GAD) 
Selectivity toward the islet cells. High 
transfection efficiency in GAD-expressing 
mouse insulinoma cells. 
 [177]  
HerPEI 
pDNA(pcDNA3-CMV-
Luc) 
anti-HER2 
The HerPEI polyplexes showed 
significantly greater transfection activity 
(up to 20-folds) than nonderivatized 
PEI-based polyplexes in the HER2 
overexpressing breast cancer cells. 
 [178]  
mannose-PEI pDNA mannose 
Dendritic cells transfected with polyplexes 
containing adenovirus particles are 
effective in activating T cells of T cell 
receptor transgenic mice in an 
antigen-specific fashion. 
 [179]  
methoxypolyethylene
glycol-PEI- 
cholesterol 
pDNA (pmIL-12) -- 
Inhibition of tumor growth enhanced when 
combined with specific chemotherapeutic 
agents. 
 [180]  
dextran-PEI pDNA -- 
Stability of the complex in the presence of 
BSA. The transfection efficiency depended 
on the molecular weight of dextran and the 
grafting degree. 
 [181]  
acid-labile PEI pDNA (pCMV-Luc) -- 
The acid-labile PEI was much less toxic 
and showed comparable transfection 
efficiency to that of PEI25K. Polyplexes 
may be rapidly degraded in acidic 
endosome. 
 [182]  
disulfide-crosslinked 
low 
molecular weight 
linear PEI- sodium 
hyaluronate 
pDNA (pBR322, 
pEGFP-C1) 
-- 
Polyplexes achieved significantly higher 
transfection efficiency than other polymer 
systems, especially in the presence of 
serum. 
 [183]  
galactosylated PLL pDNA (pCAT) galactose 
Hepatoma cell line revealed high gene 
expression. After intravenous injection, 
polyplexes were rapidly eliminated from 
the circulation and preferentially taken up 
by the liver’s parenchymal cells. 
 [184]  
Lactosylated 
PEG-siRNA/PLL 
RNAi lactose 
pH-responsive and targetable polyplexes 
exhibited significant gene silencing human 
hepatoma cells. 
 [185]  
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Table 4. Cont. 
Polymer 
Therapeutic 
agent 
Ligand Remarks Ref 
AWBP-PEG-PLL pDNA (pMNK) 
Artery wall 
binding 
peptide 
(AWBP) 
High transfection efficiency in bovine 
aorta endothelial cells and smooth muscle 
cells. 
 [186]  
Antibody-PLL 
pDNA(pSV-b-galactosi
dase) 
Anti JL1 
Polyplexes internalization into Molt 4 cells 
and human leukemia T cells. Higher in 
vitro transfection efficiency than 
polyplexes without targeting ligand. 
 [187]  
RGD-PEG-block- 
PLL 
pDNA RGD 
Synergistic effect of cyclic RGD peptide 
and disulfide cross-links to exert the 
smooth release of pDNA in the 
intracellular environment via reductive 
cleavage. Enhanced transfection efficiency 
against HeLa cells, due to a change in their 
intracellular trafficking route. 
 [188]  
 
Prevention of RSV (Respiratory Syncytial Virus) bronchiolitis, potentially reducing the later 
development of asthma associated with severe respiratory infections, was also evaluated using gene 
therapy. Plasmids expressing a short interfering RNA against the RSV-NS1 gene (siNS1), were 
complexed with chitosan. Treatment of rats with siNS1, prior to RSV exposure, was effective in 
reducing virus titers in the lung, preventing the inflammation and airway hyperresponsiveness 
associated with the infection and asthma development [189]. Similary, topical delivery of 5% 
imiquimod cream mixed with siRNA for natriuretic peptide receptor A (siNPRA) nanoparticles 
protected against asthma. In a mouse asthma model, the treatment with a imiquimod cream—
containing siNPRA chitosan nanoparticles—significantly reduced the airway hyperresponsiveness, 
eosinophilia, lung histopathology and pro-inflammatory cytokines IL-4 and IL-5 in lung homogenates. 
By combining the treatment of imiquimod and siNPRA nanoparticles, a better protection against 
airway inflammation was achieved [190].  
The feasibility of applying nanotechnology against Plasmodium falciparum, malarial parasites, was 
also investigated using antisense ODNs (phosphorothioate antisense oligodeoxynucleotides) against 
malarial topoisomerase II gene, incorporated in chitosan nanoparticles. The in vivo use of 
nanoparticles against malaria is possible only if they are harmless to red blood cells. The erythrocyte 
membrane contains anionic glycoproteins, which can interact with protonated amino groups of 
chitosan. This process induces a curvature of the cell membrane, leading to rupture and hemoglobin 
release. In the presence of plasma, however, the membrane damage is reduced, an effect that might be 
explained by adsorption of negatively charged plasma proteins on the surface of charged particles; the 
plasma shielding effect suggests that chitosan nanoparticles indeed do not harm erythrocytes in vivo. 
Nanoparticles with negative surface charge exhibited a significantly stronger inhibitory effect (׽87% 
inhibition) on the parasite growth in comparison to the positive ones (׽74% inhibition) or free ODNs 
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(׽68% inhibition). This was the first study demonstrating the susceptibility of human malaria parasite 
to antisense nanoparticles [146].  
Table 5. Other synthetic polymers for gene delivery. 
Polymer 
Therapeutic 
agent 
Remarks Ref 
poly(imidazole/ 
2-dimethylaminoethylamino)phosphazene 
pDNA 
Imidazole effect on cytotoxicity and 
transfection efficiency. Evaluation of 
half-lives under neutral and acidic 
conditions. 
 [144] 
poly[α-(4-aminobutyl)-L-glycolic acid] 
(PAGA) 
pDNA( pCAGGS-Il10, 
pCAGGS-Il4) 
Combined administration of mouse Il4 and 
Il10 plasmids prevents the development of 
autoimmune diabetes in non-obese diabetic 
mice. 
 [191] 
poly(4-hydroxy-L-proline ester) pDNA(CMV-βGal) 
The minimum viability of cells incubated 
with poly(4-hydroxy-L-proline ester) was 
85%, which is excellent when compared to 
the cases of polylysine (20%) and 
polyethylenimine (2%). 
 [192] 
poly(amido amine)s containing multiple 
disulfide linkages 
pDNA 
Buffer capacity of poly(amido amine)s in 
the pH range 7.4-5.1. High transfection 
efficiency and gene expression, in the 
presence of serum. 
 [193] 
cationic amphoteric polyamidoamine pDNA (pEGFP) 
Evaluation of toxicity and hemolytic 
activity in the pH range 4.0-7.4. Circulation 
time and organ accumulation assessment. 
Study of complex stability and transfection 
efficiency 
 [194] 
three blocks of amino acids 
Ac-(AF)6-H5-K15-NH2 (FA32) 
Doxorubicin, 
pCMV-luciferase, 
pCMV-p53 
Co-delivery of drug and gene using 
nanoparticles was demonstrated via 
confocal imaging, luciferase expression in 
the presence of doxorubicin, and synergy in 
cytotoxic effect towards HepG2 cells. 
 [166] 
N,N-diethylethylenediamine-polyurethane pDNA (pCMV-βgal) 
Cytotoxicity was substantially lower and 
transfection efficiency comparable to the 
well-known gene carrier 
poly(2-dimethylaminoethyl methacrylate 
 [195] 
 
5. Conclusion 
Nanoparticulate systems are new tools that promise a revolution in the field of drug delivery. 
Nanodevices are suited to achieve the ideal of a controlled and targeted release of bioactive molecules. 
Among the available nanosystems, self-assembled polymeric nanogels are particularly attractive, since 
they are easy to produce, affordable, and may effectively incorporate a variety of drugs, including 
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biopharmaceuticals. Furthermore, they may be decorated with different kinds of molecules, improving 
the stability and target ability. 
However, the development of these systems, consisting either of amphiphilic molecules or 
electrostatically stabilized macromolecular complexes, still require a more comprehensive 
characterization before their full potential can be exploited. The molecular organization of the 
nanogels, nanotoxicology, interaction with cells and tissues, including the in vivo biodistribution and 
intracellular trafficking, are among the issues deserving a more comprehensive characterization. 
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